FKBP family proteins: Immunophilins with versatile biological functions

NeuroSignals

Volumn 16, Issue 4, 2008, Pages 318-325

  Kang, Cong Bao ^a   Hong, Ye ^a   Dhe Paganon, Sirano ^b   Yoon, Ho Sup ^a,c  

^a NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

^b UNIVERSITY OF TORONTO   (Canada)

^c NANYANG TECHNOLOGICAL UNIVERSITY   (Singapore)

Author keywords

FK506; FK506 binding protein; Immunophilin; Immunophilin ligand; Neuroprotection; Peptidylprolyl cis trans isomerase; Rapamycin

Indexed keywords

CARRIER PROTEINS AND BINDING PROTEINS; CHAPERONE; FK 506 BINDING PROTEIN; FK 506 BINDING PROTEIN 12; GUANOSINE TRIPHOSPHATASE; IMMUNOPHILIN; LIGAND; PEPTIDYLPROLYL ISOMERASE; RAPAMYCIN; RHEB PROTEIN; TACROLIMUS; UNCLASSIFIED DRUG;

APOPTOSIS; DEGENERATIVE DISEASE; ENZYME ACTIVATION; ENZYME ACTIVITY; ENZYME INHIBITION; HUMAN; LYMPHOCYTE ACTIVATION; NERVE CELL; NEUROPROTECTION; NONHUMAN; PROTEIN BINDING; PROTEIN DOMAIN; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN INTERACTION; PROTEIN MOTIF; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; PROTEIN TRANSPORT; REVIEW; T LYMPHOCYTE;

ANIMALS; BRAIN ISCHEMIA; HUMANS; IMMUNOPHILINS; LYMPHOCYTE ACTIVATION; MODELS, IMMUNOLOGICAL; MODELS, MOLECULAR; MOLECULAR CHAPERONES; NERVE TISSUE PROTEINS; NEURONS; OXIDATIVE STRESS; PROTEIN BINDING; PROTEIN CONFORMATION; PROTEIN FOLDING; PROTEIN INTERACTION MAPPING; PROTEIN STRUCTURE, TERTIARY; RATS; STEM CELLS; STRUCTURE-ACTIVITY RELATIONSHIP; T-LYMPHOCYTES; TACROLIMUS; TACROLIMUS BINDING PROTEINS;

EID: 57149093203     PISSN: 1424862X     EISSN: None     Source Type: Journal    
DOI: 10.1159/000123041     Document Type: Review

References (64)

1. Harding MW, Galat A, Uehling DE, Schreiber SL: A receptor for the immunosuppressant FK506 is a cis-trans peptidyl-prolyl isomerase. Nature 1989;341:758-760.
2. Siekierka JJ, Hung SH, Poe M, Lin CS, Sigal NH: A cytosolic binding protein for the immunosuppressant FK506 has peptidyl-prolyl isomerase activity but is distinct from cyclophilin. Nature 1989;341:755-757.
3. Galat A: Peptidylprolyl cis/trans isomerases (immunophilins): biological diversity - targets - functions. Curr Top Med Chem 2003;3:1315-1347.
4. Huai Q, Kim HY, Liu Y, Zhao Y, Mondragon A, Liu JO, Ke H: Crystal structure of calcineurin-cyclophilin-cyclosporin shows common but distinct recognition of immunophilin-drug complexes. Proc Natl Acad Sci USA 2002;99:12037-12042.
5. Ke H, Huai Q: Structures of calcineurin and its complexes with immunophilins-immunosuppressants. Biochem Biophys Res Commun 2003;311:1095-1102.
6. Sharma VK, Li B, Khanna A, Sehajpal PK, Suthanthiran M: Which way for drug-mediated immunosuppression? Curr Opin Immunol 1994;6:784-790.
7. Dawson TM, Steiner JP, Lyons WE, Fotuhi M, Blue M, Snyder SH: The immunophilins, FK506 binding protein and cyclophilin, are discretely localized in the brain: relationship to calcineurin. Neuroscience 1994;62:569-580.
8. Fischer S, Michnick S, Karplus M: A mechanism for rotamase catalysis by the FK506-binding protein (FKBP). Biochemistry 1993;32:13830-13837.
9. Galat A: Sequence diversification of the FK506-binding proteins in several different genomes. Eur J Biochem 2000;267:4945-4959.
10. Maruyama T, Suzuki R, Furutani M: Archaeal peptidyl prolyl cis-trans isomerases (PPIases) update 2004. Front Biosci 2004;9:1680-1720.
11. Suzuki R, Nagata K, Yumoto F, Kawakami M, Nemoto N, Furutani M, Adachi K, Maruyama T, Tanokura M: Three-dimensional solution structure of an archaeal FKBP with a dual function of peptidyl prolyl cis-trans isomerase and chaperone-like activities. J Mol Biol 2003;328:1149-1160.
12. Breiman A, Camus I: The involvement of mammalian and plant FK506-binding proteins (FKBPs) in development. Transgenic Res 2002;11:321-335.
13. Monaghan P, Bell A: A Plasmodium falciparum FK506-binding protein (fkbp) with peptidyl-prolyl cis-trans isomerase and chaperone activities. Mol Biochem Parasitol 2005;139:185-195.
14. Kang CB, Feng L, Chia J, Yoon HS: Molecular characterization of FK-506 binding protein 38 and its potential regulatory role on the anti-apoptotic protein Bcl-2. Biochem Biophys Res Commun 2005;337:30-38.
15. Gothel SF, Marahiel MA: Peptidyl-prolyl cis-trans isomerases, a superfamily of ubiquitous folding catalysts. Cell Mol Life Sci 1999;55:423-436.
16. Harrar Y, Bellini C, Faure JD: FKBPs: at the crossroads of folding and transduction. Trends Plant Sci 2001;6:426-431.
17. Brillantes AB, Ondrias K, Scott A, Kobrinsky E, Ondriasova E, Moschella MC, Jayaraman T, Landers M, Ehrlich BE, Marks AR: Stabilization of calcium release channel (ryanodine receptor) function by FK506-binding protein. Cell 1994;77:513-523.
18. Wang T, Donahoe PK: The immunophilin FKBP12: a molecular guardian of the TGF-β family type I receptors. Front Biosci 2004;9:619-631.
19. Jayaraman T, Brillantes AM, Timerman AP, Fleischer S, Erdjument-Bromage H, Tempst P, Marks AR: FK506-binding protein associated with the calcium release channel (ryanodine receptor). J Biol Chem 1992;267:9474-9477.
20. Timerman AP, Ogunbumni E, Freund E, Wiederrecht G, Marks AR, Fleischer S: The calcium release channel of sarcoplasmic reticulum is modulated by FK-506-binding protein. Dissociation and reconstitution of FKBP-12 to the calcium release channel of skeletal muscle sarcoplasmic reticulum. J Biol Chem 1993;268:22992-22999.
21. Gaburjakova M, Gaburjakova J, Reiken S, Huang F, Marx SO, Rosemblit N, Marks AR: FKBP12 binding modulates ryanodine receptor channel gating. J Biol Chem 2001;276:16931-16935.
22. 2+ release channels (ryanodine receptors). Science 1998;281:818-821.
23. Long C, Cook LG, Wu GY, Mitchell BM: Removal of FKBP12/12.6 from endothelial ryanodine receptors leads to an intracellular calcium leak and endothelial dysfunction. Arterioscler Thromb Vasc Biol 2007;27:1580-1586.
24. Cameron AM, Nucifora FC Jr, Fung ET, Livingston DJ, Aldape RA, Ross CA, Snyder SH: FKBP12 binds the inositol 1,4,5-trisphosphate receptor at leucine-proline (1400-1401) and anchors calcineurin to this FK506-like domain. J Biol Chem 1997;272:27582-27588.
25. 2+ flux. Cell 1995;83:463-472.
26. Wang T, Donahoe PK, Zervos AS: Specific interaction of type I receptors of the TGF-β family with the immunophilin FKBP-12. Science 1994;265:674-676.
27. Yamaguchi T, Kurisaki A, Yamakawa N, Minakuchi K, Sugino H: FKBP12 functions as an adaptor of the Smad7-Smurf1 complex on activin type I receptor. J Mol Endocrinol 2006;36:569-579.
28. Lopez-Ilasaca M, Schiene C, Kullertz G, Tradler T, Fischer G, Wetzker R: Effects of FK506-binding protein 12 and FK506 on autophosphorylation of epidermal growth factor receptor. J Biol Chem 1998;273:9430-9434.
29. Lam E, Martin M, Wiederrecht G: Isolation of a cDNA encoding a novel human FK506-binding protein homolog containing leucine zipper and tetratricopeptide repeat motifs. Gene 1995;160:297-302.
30. Shirane M, Nakayama KI: Inherent calcineurin inhibitor FKBP38 targets Bcl-2 to mitochondria and inhibits apoptosis. Nat Cell Biol 2003;5:28-37.
31. Petros AM, Medek A, Nettesheim DG, Kim DH, Yoon HS, Swift K, Matayoshi ED, Oltersdorf T, Fesik SW: Solution structure of the antiapoptotic protein Bcl-2. Proc Natl Acad Sci USA 2001;98:3012-3017.
32. Kang CB, Tai J, Chia J, Yoon HS: The flexible loop of bcl-2 is required for molecular interaction with immunosuppressant FK-506-binding protein 38 (FKBP38). FEBS Lett 2005;579:1469-1476.
33. Wang HQ, Nakaya Y, Du Z, Yamane T, Shirane M, Kudo T, Takeda M, Takebayashi K, Noda Y, Nakayama KI, Nishimura M: Interaction of presenilins with FKBP38 promotes apoptosis by reducing mitochondrial Bcl-2. Hum Mol Genet 2005;14:1889-1902.
34. 2+ is inhibited by HSP90. J Biol Chem 2007;282:15341-15348.
35. Griffith JP, Kim JL, Kim EE, Sintchak MD, Thomson JA, Fitzgibbon MJ, Fleming MA, Caron PR, Hsiao K, Navia MA: X-ray structure of calcineurin inhibited by the immunophilin-immunosuppressant FKBP12-FK506 complex. Cell 1995;82:507-522.
36. Weiwad M, Kullertz G, Schutkowski M, Fischer G: Evidence that the substrate backbone conformation is critical to phosphorylation by p42 MAP kinase. FEBS Lett 2000;478:39-42.
37. Bai X, Ma D, Liu A, Shen X, Wang QJ, Liu Y, Jiang Y: Rheb activates mTOR by antagonizing its endogenous inhibitor, FKBP38. Science 2007;318:977-980.
38. Lebeau MC, Myagkikh I, Rouviere-Fourmy N, Baulieu EE, Klee CB: Rabbit FKBP-59/HBI does not inhibit calcineurin activity in vitro. Biochem Biophys Res Commun 1994;203:750-755.
39. Wiederrecht G, Hung S, Chan HK, Marcy A, Martin M, Calaycay J, Boulton D, Sigal N, Kincaid RL, Siekierka JJ: Characterization of high molecular weight FK-506 binding activities reveals a novel FK-506-binding protein as well as a protein complex. J Biol Chem 1992;267:21753-21760.
40. Davies TH, Sanchez ER: FKBP52. Int J Biochem Cell Biol 2005;37:42-47.
41. Sinars CR, Cheung-Flynn J, Rimerman RA, Scammell JG, Smith DF, Clardy J: Structure of the large FK506-binding protein FKBP51, an HSP90-binding protein and a component of steroid receptor complexes. Proc Natl Acad Sci USA 2003;100:868-873.
42. r 90,000 heat shock protein: main structural features of a mammalian p59 protein. Proc Natl Acad Sci USA 1992;89:6270-6274.
43. Miyata Y, Chambraud B, Radanyi C, Leclerc J, Lebeau MC, Renoir JM, Shirai R, Catelli MG, Yahara I, Baulieu EE: Phosphorylation of the immunosuppressant FK506-binding protein FKBP52 by casein kinase II: regulation of HSP90-binding activity of FKBP52. Proc Natl Acad Sci USA 1997;94:14500-14505.
44. Wu B, Li P, Liu Y, Lou Z, Ding Y, Shu C, Ye S, Bartlam M, Shen B, Rao Z: 3D structure of human FK506-binding protein 52: implications for the assembly of the glucocorticoid receptor/HSP90/immunophilin heterocomplex. Proc Natl Acad Sci USA 2004;101:8348-8353.
45. 15N resonance assignments of the N-terminal domain of FKBP38 (FKBP38NTD). J Biomol NMR 2006;36(suppl 1):37.
46. Maestre-Martinez M, Edlich F, Jarczowski F, Weiwad M, Fischer G, Lucke C: Solution structure of the FK506-binding domain of human FKBP38. J Biomol NMR 2006;34:197-202.
47. Chambraud B, Rouviere-Fourmy N, Radanyi C, Hsiao K, Peattie DA, Livingston DJ, Baulieu EE: Overexpression of p59-HBI (FKBP59), full length and domains, and characterization of PPIase activity. Biochem Biophys Res Commun 1993;196:160-166.
48. Denny WB, Prapapanich V, Smith DF, Scammell JG: Structure-function analysis of squirrel monkey FK506-binding protein 51, a potent inhibitor of glucocorticoid receptor activity. Endocrinology 2005;146:3194-3201.
49. 2+/calmodulin. EMBO J 2005;24:2688-2699.
50. Lyons WE, George EB, Dawson TM, Steiner JP, Snyder SH: Immunosuppressant FK506 promotes neurite outgrowth in cultures of PC12 cells and sensory ganglia. Proc Natl Acad Sci USA 1994;91:3191-3195.
51. Lyons WE, Steiner JP, Snyder SH, Dawson TM: Neuronal regeneration enhances the expression of the immunophilin FKBP-12. J Neurosci 1995;15:2985-2994.
52. Poulter MO, Payne KB, Steiner JP: Neuroimmunophilins: a novel drug therapy for the reversal of neurodegenerative disease? Neuroscience 2004;128:1-6.
53. Zhang C, Steiner JP, Hamilton GS, Hicks TP, Poulter MO: Regeneration of dopaminergic function in 6-hydroxydopamine-lesioned rats by neuroimmunophilin ligand treatment. J Neurosci 2001;21:RC156.
54. Pong K, Zaleska MM: Therapeutic implications for immunophilin ligands in the treatment of neurodegenerative diseases. Curr Drug Targets CNS Neurol Disord 2003;2:349-356.
55. Guo X, Dawson VL, Dawson TM: Neuroimmunophilin ligands exert neuroregeneration and neuroprotection in midbrain dopaminergic neurons. Eur J Neurosci 2001;13:1683-1693.
56. Ross DT, Guo H, Howorth P, Chen Y, Hamilton GS, Steiner JP: The small molecule FKBP ligand GPI 1046 induces partial striatal re-innervation after intranigral 6-hydroxydopamine lesion in rats. Neurosci Lett 2001;297:113-116.
57. Steiner JP, Hamilton GS, Ross DT, Valentine HL, Guo H, Connolly MA, Liang S, Ramsey C, Li JH, Huang W, Howorth P, Soni R, Fuller M, Sauer H, Nowotnik AC, Suzdak PD: Neurotrophic immunophilin ligands stimulate structural and functional recovery in neurodegenerative animal models. Proc Natl Acad Sci USA 1997;94:2019-2024.
58. Wu YQ, Wilkinson DE, Limburg D, Li JH, Sauer H, Ross D, Liang S, Spicer D, Valentine H, Fuller M, Guo H, Howorth P, Soni R, Chen Y, Steiner JP, Hamilton GS: Synthesis of ketone analogues of prolyl and pipecolyl ester FKBP12 ligands. J Med Chem 2002;45:3558-3568.
59. Costantini LC, Cole D, Chaturvedi P, Isacson O: Immunophilin ligands can prevent progressive dopaminergic degeneration in animal models of Parkinson's disease. Eur J Neurosci 2001;13:1085-1092.
60. Edlich F, Weiwad M, Wildemann D, Jarczowski F, Kilka S, Moutty MC, Jahreis G, Lucke C, Schmidt W, Striggow F, Fischer G: The specific FKBP38 inhibitor N-(N′,N′-dimethylcarboxamidomethyl)-cycloheximide has potent neuroprotective and neurotrophic properties in brain ischemia. J Biol Chem 2006;281:14961-14970.
61. Tanaka K, Fujita N, Higashi Y, Ogawa N: Neuroprotective and antioxidant properties of FKBP-binding immunophilin ligands are independent on the FKBP12 pathway in human cells. Neurosci Lett 2002;330:147-150.
62. Christner C, Herdegen T, Fischer G: FKBP ligands as novel therapeutics for neurological disorders. Mini Rev Med Chem 2001;1:377-397.
63. Avramut M, Achim CL: Immunophilins and their ligands: Insights into survival and growth of human neurons. Physiol Behav 2002;77:463-468.
64. Steiner JP, Dawson TM, Fotuhi M, Glatt CE, Snowman AM, Cohen N, Snyder SH: High brain densities of the immunophilin FKBP colocalized with calcineurin. Nature 1992;358:584-587.